Shopping Cart
Remove All
Your shopping cart is currently empty
CA-4948 (Emavusertib) is a potent IRAK4/FLT3 inhibtor. CA-4948 with anti-tumor activity.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $30 | In Stock | In Stock | |
| 2 mg | $44 | In Stock | In Stock | |
| 5 mg | $70 | In Stock | In Stock | |
| 10 mg | $89 | In Stock | In Stock | |
| 25 mg | $178 | In Stock | In Stock | |
| 50 mg | $328 | In Stock | In Stock | |
| 100 mg | $563 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $76 | In Stock | In Stock |
| Description | CA-4948 (Emavusertib) is a potent IRAK4/FLT3 inhibtor. CA-4948 with anti-tumor activity. |
| In vitro | CA-4948, demonstrated good cellular activity in ABC DLBCL and AML cell lines.?Inhibition of TLR signaling leading to decreased IL-6 levels was also observed in whole blood assays.?CA-4948 demonstrated moderate to high selectivity in a panel of 329 kinases as well as exhibited desirable ADME and PK profiles including good oral bioavailability in mice, rat, and dog and showed >90% tumor growth inhibition in relevant tumor models with excellent correlation with in vivo PD modulation.?CA-4948 was well tolerated in toxicity studies in both mouse and dog at efficacious exposure.?The overall profile of CA-4948 prompted us to select it as a clinical candidate for evaluation in patients with relapsed or refractory hematologic malignancies including non-Hodgkin lymphoma and acute myeloid leukemia[2]. |
| Synonyms | Emavusertib |
| Molecular Weight | 491.5 |
| Formula | C24H25N7O5 |
| Cas No. | 1801344-14-8 |
| Smiles | Cc1cc(ccn1)-c1nc(co1)C(=O)Nc1cc2oc(nc2nc1N1CC[C@@H](O)C1)N1CCOCC1 |
| Relative Density. | 1.457 g/cm3 (Predicted) |
| Color | Yellow |
| Appearance | Solid |
| Storage | store at low temperature,keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | H2O: < 0.1 mg/mL (insoluble) DMSO: 27.78 mg/mL (56.52 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 2 mg/mL (4.07 mM), Sonication is recommeded. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.